Price T Rowe Associates Inc. MD Raises Stock Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Price T Rowe Associates Inc. MD lifted its holdings in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 17.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 22,265 shares of the biopharmaceutical company’s stock after purchasing an additional 3,370 shares during the quarter. Price T Rowe Associates Inc. MD’s holdings in Vanda Pharmaceuticals were worth $107,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of VNDA. JPMorgan Chase & Co. grew its holdings in shares of Vanda Pharmaceuticals by 16.1% during the third quarter. JPMorgan Chase & Co. now owns 160,722 shares of the biopharmaceutical company’s stock worth $754,000 after purchasing an additional 22,249 shares in the last quarter. SG Americas Securities LLC boosted its stake in Vanda Pharmaceuticals by 26.8% in the fourth quarter. SG Americas Securities LLC now owns 25,861 shares of the biopharmaceutical company’s stock worth $124,000 after buying an additional 5,459 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its stake in Vanda Pharmaceuticals by 4.9% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 819,382 shares of the biopharmaceutical company’s stock worth $3,925,000 after buying an additional 38,449 shares in the last quarter. Monaco Asset Management SAM boosted its stake in Vanda Pharmaceuticals by 92.8% in the fourth quarter. Monaco Asset Management SAM now owns 392,262 shares of the biopharmaceutical company’s stock worth $1,879,000 after buying an additional 188,836 shares in the last quarter. Finally, American Century Companies Inc. boosted its stake in Vanda Pharmaceuticals by 2.1% in the fourth quarter. American Century Companies Inc. now owns 300,276 shares of the biopharmaceutical company’s stock worth $1,438,000 after buying an additional 6,079 shares in the last quarter. Hedge funds and other institutional investors own 88.14% of the company’s stock.

Insider Activity at Vanda Pharmaceuticals

In other news, CEO Mihael Hristos Polymeropoulos purchased 10,000 shares of the stock in a transaction that occurred on Friday, February 28th. The stock was bought at an average cost of $4.76 per share, for a total transaction of $47,600.00. Following the acquisition, the chief executive officer now directly owns 2,361,730 shares of the company’s stock, valued at $11,241,834.80. This represents a 0.43% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders bought 32,000 shares of company stock worth $151,180 in the last three months. 10.00% of the stock is owned by insiders.

Vanda Pharmaceuticals Stock Performance

NASDAQ:VNDA opened at $4.16 on Friday. Vanda Pharmaceuticals Inc. has a fifty-two week low of $3.81 and a fifty-two week high of $6.75. The firm has a market cap of $245.17 million, a PE ratio of -13.00 and a beta of 0.69. The business has a 50 day moving average price of $4.43 and a 200-day moving average price of $4.63.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) EPS for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.05. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. The company had revenue of $50.04 million during the quarter, compared to analyst estimates of $45.13 million. Research analysts predict that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current year.

Analysts Set New Price Targets

VNDA has been the subject of several research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $13.00 target price on shares of Vanda Pharmaceuticals in a research note on Wednesday. StockNews.com initiated coverage on Vanda Pharmaceuticals in a research note on Wednesday, February 5th. They issued a “hold” rating for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Vanda Pharmaceuticals in a research note on Wednesday, May 7th.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.